Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

itive patients who were naive to antiretroviral treatment. Nine out of 12 patients in each of four cohorts received RDEA806. The primary efficacy end point was the change from baseline in plasma viral load. Top-line results from all four cohorts showed the following:

-- The median reduction in plasma viral load at nadir was 1.9 - 2.1 log copies/ml (placebo adjusted) for all four treatment cohorts.

-- Patients receiving either 800 mg or 1000 mg once daily with the enteric-coated tablet formulation, and patients receiving 400 mg twice daily with the capsule formulation, experienced a 1.8 - 1.9 log median reduction in plasma viral load (adjusted for placebo) on Day 8; the 600 mg capsule formulation given once daily produced a 1.4 log median reduction (adjusted for placebo) at this time point.

-- There were no serious adverse events, ECG-related adverse events, or drug-related rash reported in any cohort. The incidence of CNS side effects was similar between drug and placebo. Administration of the highest dose on an empty stomach showed an increase in gastrointestinal side effects, but these effects were generally transient and mild.

-- There were no premature discontinuations in any cohort.

-- Based on the results generated in this trial, the doses planned for the Phase 2b program will be 600 mg, 800 mg and 1000 mg once daily with the enteric-coated tablet given with or without food.

"We are very pleased to announce the successful completion of the Phase 2a program with RDEA806," said Barry D. Quart, PharmD, Ardea's President and CEO. "Based on the excellent antiviral activity observed with once-daily dosing of the enteric-coated oral formulation, we plan to proceed in the third quarter of this year with a multi-national Phase 2b study comparing 600 mg, 800 mg and 1000 mg once daily doses of RDEA806 to efavirenz (SUSTIVA(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir)." '/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
(Date:7/31/2014)... -- Decision Resources Group is launching an extension of its ... include ChinaTrack; the new capabilities track the ... providing detailed brand-level share tracking and analytics. ChinaTrack also ... Other key capabilities of the new line extension: ... end-user surveys of healthcare facilities, ChinaTrack data is paired ...
(Date:7/31/2014)... , July 31, 2014  A substantial ... make decisions about which therapies are included in ... placement, according to a new Manhattan Research study, ... . The study finds that P&T committee members ... benefits managers (PBMs) have set a high bar ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... Helix Health, the first U.S.,stand-alone genomic medicine practice, is ... 1:00-2:30 PM EDT examining:, How Genomic Medicine ... To register, point your browser here, http://event.netbriefings.com/event/helixhealth/register.html ... States are diagnosed with cancer.,There is a growing number ...
... Scientists Refused To Do,Illustrates Vaccine Program And Mercury ... Findings released Friday,showed that infant monkeys given ... Academy of Pediatrics (AAP) exhibited autism-like,symptoms. Lead investigator ... presented study results at the International Meeting for,Autism ...
Cached Medicine Technology:Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer 2Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists 2
(Date:7/31/2014)... Ticket Down is a reliable ... Sporting Goods Park in suburban Denver on Tuesday, September ... team has found a second home competing on American soil. ... playing international friendly games and will look to have another ... Park in Commerce City, Colorado. The match will be Mexico’s ...
(Date:7/31/2014)... New Jersey (PRWEB) July 31, 2014 ... and administer the application of topical fluoride treatments to ... dental caries and help with tooth sensitivity in patients ... Latin, is an infection that is commonly known as ... the hard tissues of the teeth. , ...
(Date:7/31/2014)... Infection prevention and control is the most significant ... the pharma, medical device, and food industries. Disinfection and ... equipment types; the two procedures prevent the spread of ... , The world market for infection prevention and control ... of about 7.5% through to 2018. The factors fuelling ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... is now available as an open access journal ... P-LinK: A method for generating multicomponent , ... sensors , A workflow to increase ... next-generation sequencing , Quantification of particle-conjugated ...
(Date:7/31/2014)... developed a novel method for creating self-assembled protein/polymer ... living cells. The work offers a promising new ... tissue engineering applications. The findings were published in ... International Edition . , "We have demonstrated that, ... can form completely new types of aggregates. These ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal 2Health News:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal 3Health News:Carnegie Mellon chemists create nanofibers using unprecedented new method 2
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) ... performance, but not necessarily in autistic children, a new ... spelling and math abilities of 30, "high-functioning" 9-year-old autistic ... parental and teacher reports at ages 6 and 9. ...
... cells (CSCs), the aggressive cells thought to be resistant to ... estrogen via a pathway that mirrors normal stem cell development. ... of breast CSCs, a finding that suggests a new drug ... the Proceedings of the National Academy of Sciences ...
... Exercising to music reduces the risk of falls among elderly ... adults, mostly women, average age 75.5 years, who were at ... intervention group that did a music-based multitask exercise program or ... six months, the participants switched groups for the next six ...
... , TUESDAY, Nov. 23 (HealthDay News) -- Implantable ... while preventing sudden death among heart failure patients ... real-world situations as they are in controlled study ... based on an analysis of nearly 186,000 patients ...
... the dangers of excessive fructose in diet. A new review ... of the American Society of Nephrology ( JASN ) ... Richard J. Johnson, MD and Takahiko Nakagawa, MD (Division ... concise overview of recent clinical and experimental studies to understand ...
... 22 (HealthDay News) -- Deaths from congenital heart defects in ... continuing a decades-long decline, a new study finds. Congenital ... These include a variety of conditions that range from mild ... as irregular heartbeats, congestive heart failure and high blood pressure ...
Cached Medicine News:Health News:For Autistic Kids, IQ May Not Predict School Achievement 2Health News:For Autistic Kids, IQ May Not Predict School Achievement 3Health News:Discovery halts breast cancer stem cells 2Health News:Practicing Moving to Music May Help Elderly Avoid Falls 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3Health News:Deaths From Congenital Heart Defects on the Decline 2
... (TSH) is a 32 kDa glycoprotein secreted ... pituitary gland [1]. The structure of human ... pituitary and placental gonadotropins, consisting of an ... these hormones and a unique beta-subunit, which ...
... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
... produced primarily by 5-monodeioination of thyroxine (T4) ... T3 production occurs at a rate which ... Release of T3 from the thyroid gland ... compared to 80-100 micrograms/day for T4. In ...
... protein-3 (IGFBP-3) is the main binding protein for ... component of the ~150 kDa ternary complex. This ... or IGF-II and ALS, allowing IGFBP-3, along with ... The molar concentration of IGFBP-3 in normal serum ...
Medicine Products: